Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier

DOI: 10.1038/aps.2017.44

Keywords: NLG919, checkpoint, immunotherapy, prodrug micelles, doxorubicin, co-delivery, 4T1.2 mouse breast cancer cells, PC-3 human prostate cancer cells

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text